PharmaPoint: Meningococcal Vaccines - United Kingdom Drug Forecast and Market Analysis to 2022
GlobalData has released its...
3 Introduction 6
3.1 Catalyst 6
3.2 Related Reports 7
3.3 Upcoming Related Reports 9
4 Disease Overview 10
4.1 Etiology An...
7.2.7 Unmet Need: Increased Patient Awareness And Education 50
7.3 Unmet Needs Gap Analysis 51
7.4 Opportunities 52
7.4.1 ...
10.6.3 Global Head Of Healthcare 109
10.7 About Globaldata 111
10.8 Contact Us 111
10.9 Disclaimer 111
ResearchMoz(http://...
Upcoming SlideShare
Loading in …5
×

PharmaPoint: Meningococcal Vaccines - United Kingdom Drug Market 2022:Industry Trends, Size and Shares Research Report

173 views

Published on

Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofis Menactra and Novartis Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment. GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022.

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
173
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

PharmaPoint: Meningococcal Vaccines - United Kingdom Drug Market 2022:Industry Trends, Size and Shares Research Report

  1. 1. PharmaPoint: Meningococcal Vaccines - United Kingdom Drug Forecast and Market Analysis to 2022 GlobalData has released its new Country report, PharmaPoint: Meningococcal Vaccines United Kingdom Drug Forecast and Market Analysis to 2022. Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofis Menactra and Novartis Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment. GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022. GlobalData predicts that relative patient share for the three MenC conjugate vaccines will shift due to changes being made to the UK MenC schedule (DOH, 2013b). Meningitec will lose sales due to its elimination from the single primary dose, with patient share expected to be made up by Menjugate and NeisVac-C. Scope Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on the key drugs in the UK including product description, safety and efficacy profiles as well as a SWOT analysis. Sales forecast for the top drugs in the UK from 2012-2022. Analysis of the impact of key events as well the drivers and restraints affecting the UK Meningococcal Vaccines market. Reasons to buy Understand and capitalize by identifying products that are most likely to ensure a robust return Stay ahead of the competition by understanding the changing competitive landscape for Meningococcal Vaccines Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential Make more informed business decisions from insightful and in-depth analysis of drug performance Obtain sales forecast for drugs from 2012-2022 in the UK table Of Contents 1 Table Of Contents 1 1.1 List Of Tables 3 1.2 List Of Figures 3 2 Executive Summary 4 2.1 Sales For Meningococcal Vaccine In The United Kingdom 4 2.2 What Do The Physicians Think? 5 PharmaPoint: Meningococcal Vaccines - United Kingdom Drug Forecast and Market Analysis to 2022
  2. 2. 3 Introduction 6 3.1 Catalyst 6 3.2 Related Reports 7 3.3 Upcoming Related Reports 9 4 Disease Overview 10 4.1 Etiology And Pathophysiology 11 4.1.1 Etiology 11 4.1.2 Pathophysiology 12 4.2 Symptoms 13 4.3 Prognosis 14 5 Disease Management 14 5.1 Meningococcal Immunization Policy 15 5.2 Uk 17 5.2.1 Meningococcal Immunization Recommendations And Policies 17 5.2.2 Clinical Practice 19 6 Competitive Assessment 20 6.1 Overview 20 6.2 Strategic Competitor Assessment 20 6.3 Product Profiles Major Brands 22 6.3.1 Menveo 22 6.3.2 Nimenrix 26 6.3.3 Menitorix 29 6.3.4 Meningitec 32 6.3.5 Menjugate 35 6.3.6 Neisvac-c 38 6.3.7 Bexsero 41 7 Opportunity And Unmet Need 43 7.1 Overview 43 7.2 Unmet Needs 44 7.2.1 Unmet Need: Protection Against Serogroup B Disease 44 7.2.2 Unmet Need: A Pentavalent (menabcwy) Vaccine 44 7.2.3 Unmet Need: More Cost-effective Vaccines 46 7.2.4 Unmet Need: Improved Duration Of Immunity In Children And Adolescents 46 7.2.5 Unmet Need: Immunogenic Infant Vaccines 48 7.2.6 Unmet Need: Improved Vaccination Coverage Rates 49 PharmaPoint: Meningococcal Vaccines - United Kingdom Drug Forecast and Market Analysis to 2022
  3. 3. 7.2.7 Unmet Need: Increased Patient Awareness And Education 50 7.3 Unmet Needs Gap Analysis 51 7.4 Opportunities 52 7.4.1 Opportunity: Broadening Serogroup Protection With New And Existing Antigen Combinations 52 7.4.2 Opportunity: Improving Immune Response Duration With Adjuvants 53 7.4.3 Opportunity: Developing More Cost-effective Vaccines By Partnering With Manufacturers In Emerging Markets 54 8 Pipeline Assessment 54 8.1 Overview 54 8.2 Promising Vaccines In Clinical Development 54 8.2.1 Mnb Rlp2086 58 8.3 Promising Vaccines In Early Clinical Development 63 8.3.1 Meninge Acyw Conj. 64 8.3.2 Menabcwy 68 8.3.3 Menc Conjugate 71 8.3.4 Heptavalent Dtp-hib-hepb-ipv-menc 74 9 Market Outlook 76 9.1 United Kingdom 76 9.1.1 Forecast 76 9.1.2 Key Events 79 9.1.3 Drivers And Barriers 80 10 Appendix 81 10.1 Bibliography 81 10.2 Abbreviations 92 10.3 Methodology 94 10.4 Forecasting Methodology 94 10.4.1 Vaccine Coverage 95 10.4.2 Vaccine Approval Vs. Routine Schedule Inclusion 95 10.4.3 Vaccines Included 96 10.4.4 Key Launch Dates 97 10.4.5 General Pricing Assumptions 98 10.4.6 Individual Vaccine Assumptions 99 10.4.7 Pricing Of Pipeline Agents 103 10.5 Physicians And Specialists Included In This Study 105 10.6 About The Authors 109 10.6.1 Authors 109 10.6.2 Reviewers 109 PharmaPoint: Meningococcal Vaccines - United Kingdom Drug Forecast and Market Analysis to 2022
  4. 4. 10.6.3 Global Head Of Healthcare 109 10.7 About Globaldata 111 10.8 Contact Us 111 10.9 Disclaimer 111 ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Website: http://www.researchmoz.us/ PharmaPoint: Meningococcal Vaccines - United Kingdom Drug Forecast and Market Analysis to 2022

×